title: Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients.
abstract: OBJECTIVE
  To investigate the effects of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor activator, on body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients.
  
  
  METHODS
  A total of 328 Chinese overweight and obese type 2 diabetic patients were included in this multi-center, open-labeled and self-controlled clinical study. The patients were subcutaneously injected with liraglutide once daily for 24 weeks as add-on therapy to their previous hypoglycemic treatments. Statistical analyses were performed using SPSS software package version 11.5 for Windows.
  
  
  RESULTS
  Liraglutide treatment caused significant reduction of the mean body weight (from 86.61±14.09 to 79.10±13.55 kg) and waist circumference (from 101.81±13.96 to 94.29±14.17 cm), resulting in body weight lose of 5%-10% in 43.67% patients, and body weight loss above 10% in 34.06% patients, who had significant lower plasma creatinine levels. Baseline waist circumference, BMI and HOMA-IR were independently correlated with the body weight loss. Furthermore, liraglutide treatment significantly decreased HbA1c levels (from 8.66%±2.17% to 6.92%±0.95%) with HbA1c<7.0% in 35.37% patients, who had a significantly lower baseline level of HbA1c, but higher baseline levels of C peptide and glucagon. Moreover, liraglutide treatment resulted in greater body weight loss in patients with a long duration of diabetes, and better glycemic control in patients with a short duration of diabetes.
  
  
  CONCLUSIONS
  Liraglutide significantly reduces body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients. Patients with apparent visceral obesity, insulin resistance and a long duration of diabetes may have greater body weight loss; whereas patients with high insulin-secreting ability, hyperglucagonemia, and short-duration diabetes may obtain better glycemic control with liraglutide.
authors.affiliation: The General Hospital of Tianjin Medical University, Tianjin 300052, China.
authors.forename: Ping
authors.initials: P
authors.lastname: Feng
authors.affiliation: 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Key Laboratory of Hormone and Development (Ministry of Health), Metabolic Disease Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300070, China.
authors.forename: De-min
authors.initials: DM
authors.lastname: Yu
authors.affiliation: 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Key Laboratory of Hormone and Development (Ministry of Health), Metabolic Disease Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300070, China.
authors.forename: Li-ming
authors.initials: LM
authors.lastname: Chen
authors.affiliation: 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Key Laboratory of Hormone and Development (Ministry of Health), Metabolic Disease Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300070, China.
authors.forename: Bao-cheng
authors.initials: BC
authors.lastname: Chang
authors.affiliation: The General Hospital of Tianjin Medical University, Tianjin 300052, China.
authors.forename: Qiu-di
authors.initials: QD
authors.lastname: Ji
authors.affiliation: The General Hospital of Tianjin Medical University, Tianjin 300052, China.
authors.forename: Shu-ying
authors.initials: SY
authors.lastname: Li
authors.affiliation: The General Hospital of Tianjin Medical University, Tianjin 300052, China.
authors.forename: Mei
authors.initials: M
authors.lastname: Zhu
authors.affiliation: The Chinese PLA464 Hospital, Tianjin 300381, China.
authors.forename: Sheng-hua
authors.initials: SH
authors.lastname: Ding
authors.affiliation: The Chinese PLA464 Hospital, Tianjin 300381, China.
authors.forename: Bao-zhen
authors.initials: BZ
authors.lastname: Zhang
authors.affiliation: Department of Endocrinology, the Affiliated Hospital of Logistics University of Chinese People's Armed Police Forces, Tianjin 300162, China.
authors.forename: Su-li
authors.initials: SL
authors.lastname: Wang
authors.affiliation: Armed Police Crops Hospital, Tianjin 300162, China.
authors.forename: Hong-tao
authors.initials: HT
authors.lastname: Li
authors.affiliation: Tianjin People's Hospital, Tianjin 300121, China.
authors.forename: Jing-na
authors.initials: JN
authors.lastname: Lin
authors.affiliation: Tian Jin Shi Xian Shui Gu Hospital, Tianjin 300052, China.
authors.forename: Mao-jun
authors.initials: MJ
authors.lastname: Wang
authors.affiliation: The Second Hospital of Tianjin Medical University, Tianjin 300211, China.
authors.forename: Jian-chao
authors.initials: JC
authors.lastname: Guo
authors.affiliation: Nankai Hospital of Traditional Chinese Medicine, Affiliated with Tianjin University of Traditional Chinese Medicine, Tianjin 300102, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Liu
authors.affiliation: Nankai Hospital of Traditional Chinese Medicine, Affiliated with Tianjin University of Traditional Chinese Medicine, Tianjin 300102, China.
authors.forename: Zhong-dong
authors.initials: ZD
authors.lastname: Liu
authors.affiliation: The First Hospital Affiliated to Tianjin Medical University, Tianjin 300193, China.
authors.forename: Shen-tao
authors.initials: ST
authors.lastname: Wu
authors.affiliation: 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Key Laboratory of Hormone and Development (Ministry of Health), Metabolic Disease Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300070, China.
authors.forename: Ju-hong
authors.initials: JH
authors.lastname: Yang
mesh_terms: D044466:Asian People; D001835:Body Weight / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology*; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069450:Liraglutide; D008297:Male; D008875:Middle Aged; D050177:Overweight / Q000188:drug therapy*; D055105:Waist Circumference / Q000187:drug effects*
chemical_list: D007004:Hypoglycemic Agents; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1